Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 4—April 2026

Research

Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance

Elif Karaaslan, Amy Whitesell, Jason Malenfant, William C. Carson, Michael Townsend, Kasongo Kayembe Jolie, Enogo Koivogui, Siba Michel Grovogui, Boubacar Diallo, Nouonan Gbamou, Salomon Corvil, Sanaba Boumbaly, Lise Martel, Julie R. Sinclair, Alimou Camara, Trevor Shoemaker, Mary J. Choi, Joel M. Montgomery, Christina F. Spiropoulou, and Éric BergeronComments to Author 
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Karaaslan, A. Whitesell, J. Malenfant, W.C. Carson, M. Townsend, L. Martel, J.R. Sinclair, T. Shoemaker, M.J. Choi, J.M. Montgomery, C.T. Spiropoulou, É. Bergeron); African Field Epidemiology Network, Conakry, Guinea (K.K. Jolie, S. Corvil); Ministry of Health, Conakry (E. Koivogui, S.M. Grovogui); US Centers for Disease Control and Prevention, Conakry (B. Diallo); Agence Nationale de Sécurité Sanitaire, Conakry (N. Gbamou); International Center for Research of Tropical Infections in Guinea, N’Zerekore, Guinea (S. Boumbaly); Ministry of Higher Education, Scientific Research, and Innovation, Conakry (A. Camara); University of Georgia, Athens, Georgia, USA (É. Bergeron).

Main Article

Figure 2

Detection of ERVEBO vaccinees enhanced with EBOV sGP and VSV-P-N for study of development of multiplex assay to confirm Ebola vaccination. A–C) The log2-normalized MFI values for EBOV GP1,2 (A), EBOV sGP (B), and VSV-P-N (C) assays for US negative controls (n = 84), Tshuapa samples (n = 75), and US vaccinees (n = 48) are shown in scatter plots. Horizontal solid lines indicate medians; horizontal dotted lines indicate the assay-specific cutoff values. D–F) Receiver operating characteristic (ROC) curves (black lines) and sensitivity and specificity were measured at the defined cutoffs for EBOV GP1,2 (D), EBOV sGP (E), and VSV-P-N (F). ROC area values: D, 0.9950 (95% CI 0.9870–1.000); E, F, 1.000. Sensitivity: D, 95.8% (95% CI 86.02%–99.26%); E, 100% (95% CI 92.59%–100%); F, 100% (95% CI 92.59%–100%). Specificity: D, 98.6% (95% CI 92.83%–99.93%); E, 97.6% (95% CI 91.73%–99.58%); F, 98.8% (95% CI 93.56%–99.94%). Figure created using BioRender (https://www.biorender.com). EBOV, Ebola virus; GP, glycoprotein; MFI, mean fluorescence intensity; sGP, secreted glycoprotein; VSV-P-N, vesicular stomatitis virus nucleoprotein N-terminally fused with P peptide.

Figure 2. Detection of ERVEBO vaccinees enhanced with EBOV sGP and VSV-P-N for study of development of multiplex assay to confirm Ebola vaccination. A–C) The log2-normalized MFI values for EBOV GP1,2 (A), EBOV sGP (B), and VSV-P-N (C) assays for US negative controls (n = 84), Tshuapa samples (n = 75), and US vaccinees (n = 48) are shown in scatter plots. Horizontal solid lines indicate medians; horizontal dotted lines indicate the assay-specific cutoff values. D–F) Receiver operating characteristic (ROC) curves (black lines) and sensitivity and specificity were measured at the defined cutoffs for EBOV GP1,2 (D), EBOV sGP (E), and VSV-P-N (F). ROC area values: D, 0.9950 (95% CI 0.9870–1.000); E, F, 1.000. Sensitivity: D, 95.8% (95% CI 86.02%–99.26%); E, 100% (95% CI 92.59%–100%); F, 100% (95% CI 92.59%–100%). Specificity: D, 98.6% (95% CI 92.83%–99.93%); E, 97.6% (95% CI 91.73%–99.58%); F, 98.8% (95% CI 93.56%–99.94%). Figure created using BioRender (https://www.biorender.com). EBOV, Ebola virus; GP, glycoprotein; MFI, mean fluorescence intensity; sGP, secreted glycoprotein; VSV-P-N, vesicular stomatitis virus nucleoprotein N-terminally fused with P peptide.

Main Article

Page created: March 04, 2026
Page updated: March 30, 2026
Page reviewed: March 30, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external